Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Serlopitant Improves Psoriatic Itch in Phase 2 Study

Key clinical point: Serlopitant provides clinically meaningful improvement in psoriatic itch.

Major finding: A 4-point or greater reduction on the Worst Itch Numeric Rating Scale was achieved in 33.9% of psoriasis patients on serlopitant at 5 mg once daily and 21.1% of placebo-treated controls.

Study details: This phase 2, double-blind, 8-week, placebo-controlled randomized trial included 204 adults with plaque psoriasis study.

Disclosures: The study was funded by Menlo Therapeutics. The presenter reported receiving research funding from and/or serving as a consultant to or advisory board member for roughly two dozen pharmaceutical companies.

Citation:

Pariser DM. EADV Congress 2019.